### PART B—DRUGS FOR RARE DISEASES OR CONDITIONS

### §360aa. Recommendations for investigations of drugs for rare diseases or conditions
#### (a) Request by sponsor; response by Secretary
* The sponsor of a drug for a disease or condition which is rare in the States may request the Secretary to provide written recommendations for the non-clinical and clinical investigations which must be conducted with the drug before—

  * (1) it may be approved for such disease or condition under section 355 of this title, or

  * (2) if the drug is a biological product, it may be licensed for such disease or condition under section 262 of title 42.


* If the Secretary has reason to believe that a drug for which a request is made under this section is a drug for a disease or condition which is rare in the States, the Secretary shall provide the person making the request written recommendations for the non-clinical and clinical investigations which the Secretary believes, on the basis of information available to the Secretary at the time of the request under this section, would be necessary for approval of such drug for such disease or condition under section 355 of this title or licensing of such drug for such disease or condition under section 262 of title 42.

#### (b) Regulations
* The Secretary shall by regulation promulgate procedures for the implementation of subsection (a).

### §360bb. Designation of drugs for rare diseases or conditions
#### (a) Request by sponsor; preconditions; "rare disease or condition" defined
* (1) The manufacturer or the sponsor of a drug may request the Secretary to designate the drug as a drug for a rare disease or condition. A request for designation of a drug shall be made before the submission of an application under section 355(b) of this title for the drug, or the submission of an application for licensing of the drug under section 262 of title 42. If the Secretary finds that a drug for which a request is submitted under this subsection is being or will be investigated for a rare disease or condition and—

  * (A) if an application for such drug is approved under section 355 of this title, or

  * (B) if a license for such drug is issued under section 262 of title 42,


* the approval, certification, or license would be for use for such disease or condition, the Secretary shall designate the drug as a drug for such disease or condition. A request for a designation of a drug under this subsection shall contain the consent of the applicant to notice being given by the Secretary under subsection (b) respecting the designation of the drug.

* (2) For purposes of paragraph (1), the term "rare disease or condition" means any disease or condition which (A) affects less than 200,000 persons in the United States, or (B) affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug. Determinations under the preceding sentence with respect to any drug shall be made on the basis of the facts and circumstances as of the date the request for designation of the drug under this subsection is made.

#### (b) Notification of discontinuance of drug or application as condition
* A designation of a drug under subsection (a) shall be subject to the condition that—

  * (1) if an application was approved for the drug under section 355(b) of this title or a license was issued for the drug under section 262 of title 42, the manufacturer of the drug will notify the Secretary of any discontinuance of the production of the drug at least one year before discontinuance, and

  * (2) if an application has not been approved for the drug under section 355(b) of this title or a license has not been issued for the drug under section 262 of title 42 and if preclinical investigations or investigations under section 355(i) of this title are being conducted with the drug, the manufacturer or sponsor of the drug will notify the Secretary of any decision to discontinue active pursuit of approval of an application under section 355(b) of this title or approval of a license under section 262 of title 42.

#### (c) Notice to public
* Notice respecting the designation of a drug under subsection (a) shall be made available to the public.

#### (d) Regulations
* The Secretary shall by regulation promulgate procedures for the implementation of subsection (a).

### §360cc. Protection for drugs for rare diseases or conditions
#### (a) Exclusive approval, certification, or license
* Except as provided in subsection (b), if the Secretary—

  * (1) approves an application filed pursuant to section 355 of this title, or

  * (2) issues a license under section 262 of title 42


* for a drug designated under section 360bb of this title for a rare disease or condition, the Secretary may not approve another application under section 355 of this title or issue another license under section 262 of title 42 for the same drug for the same disease or condition for a person who is not the holder of such approved application or of such license until the expiration of seven years from the date of the approval of the approved application or the issuance of the license. Section 355(c)(2) of this title does not apply to the refusal to approve an application under the preceding sentence.

#### (b) Exceptions
* During the 7-year period described in subsection (a) for an approved application under section 355 of this title or license under section 262 of title 42, the Secretary may approve an application or issue a license for a drug that is otherwise the same, as determined by the Secretary, as the already approved drug for the same rare disease or condition if—

  * (1) the Secretary finds, after providing the holder of exclusive approval or licensure notice and opportunity for the submission of views, that during such period the holder of the exclusive approval or licensure cannot ensure the availability of sufficient quantities of the drug to meet the needs of persons with the disease or condition for which the drug was designated; or

  * (2) the holder provides the Secretary in writing the consent of such holder for the approval of other applications or the issuance of other licenses before the expiration of such seven-year period.

#### (c) Condition of clinical superiority
* #### (1) In general
  * If a sponsor of a drug that is designated under section 360bb of this title and is otherwise the same, as determined by the Secretary, as an already approved or licensed drug is seeking exclusive approval or exclusive licensure described in subsection (a) for the same rare disease or condition as the already approved drug, the Secretary shall require such sponsor, as a condition of such exclusive approval or licensure, to demonstrate that such drug is clinically superior to any already approved or licensed drug that is the same drug.

* #### (2) Definition
  * For purposes of paragraph (1), the term "clinically superior" with respect to a drug means that the drug provides a significant therapeutic advantage over and above an already approved or licensed drug in terms of greater efficacy, greater safety, or by providing a major contribution to patient care.

* #### (3) Applicability
  * This subsection applies to any drug designated under section 360bb of this title for which an application was approved under section 355 of this title or licensed under section 262 of title 42 after August 18, 2017, regardless of the date on which such drug was designated under section 360bb of this title.

#### (d) Regulations
* The Secretary may promulgate regulations for the implementation of subsection (c). Beginning on August 18, 2017, until such time as the Secretary promulgates regulations in accordance with this subsection, the Secretary may apply any definitions set forth in regulations that were promulgated prior to such date, to the extent such definitions are not inconsistent with the terms of this section, as amended by such Act.

#### (e) Demonstration of clinical superiority standard
* To assist sponsors in demonstrating clinical superiority as described in subsection (c), the Secretary—

  * (1) upon the designation of any drug under section 360bb of this title, shall notify the sponsor of such drug in writing of the basis for the designation, including, as applicable, any plausible hypothesis offered by the sponsor and relied upon by the Secretary that the drug is clinically superior to a previously approved drug; and

  * (2) upon granting exclusive approval or licensure under subsection (a) on the basis of a demonstration of clinical superiority as described in subsection (c), shall publish a summary of the clinical superiority findings.

### §360dd. Open protocols for investigations of drugs for rare diseases or conditions
* If a drug is designated under section 360bb of this title as a drug for a rare disease or condition and if notice of a claimed exemption under section 355(i) of this title or regulations issued thereunder is filed for such drug, the Secretary shall encourage the sponsor of such drug to design protocols for clinical investigations of the drug which may be conducted under the exemption to permit the addition to the investigations of persons with the disease or condition who need the drug to treat the disease or condition and who cannot be satisfactorily treated by available alternative drugs.

### §360ee. Grants and contracts for development of drugs for rare diseases and conditions
#### (a) Authority of Secretary
* The Secretary may make grants to and enter into contracts with public and private entities and individuals to assist in (1) defraying the costs of developing drugs for rare diseases or conditions, including qualified testing expenses, (2) defraying the costs of developing medical devices for rare diseases or conditions, and (3) defraying the costs of developing medical foods for rare diseases or conditions.

#### (b) Definitions
* For purposes of subsection (a):

  * (1) The term "qualified testing" means—

    * (A) human clinical testing—

      * (i) which is carried out under an exemption for a drug for a rare disease or condition under section 355(i) of this title (or regulations issued under such section); and

      * (ii) which occurs before the date on which an application with respect to such drug is submitted under section 355(b) of this title or under section 262 of title 42;


    * (B) preclinical testing involving a drug for a rare disease or condition which occurs after the date such drug is designated under section 360bb of this title and before the date on which an application with respect to such drug is submitted under section 355(b) of this title or under section 262 of title 42; and

    * (C) prospectively planned and designed observational studies and other analyses conducted to assist in the understanding of the natural history of a rare disease or condition and in the development of a therapy, including studies and analyses to—

      * (i) develop or validate a drug development tool related to a rare disease or condition; or

      * (ii) understand the full spectrum of the disease manifestations, including describing genotypic and phenotypic variability and identifying and defining distinct subpopulations affected by a rare disease or condition.


  * (2) The term "rare disease or condition" means (1) in the case of a drug, any disease or condition which (A) affects less than 200,000 persons in the United States, or (B) affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug, (2) in the case of a medical device, any disease or condition that occurs so infrequently in the United States that there is no reasonable expectation that a medical device for such disease or condition will be developed without assistance under subsection (a), and (3) in the case of a medical food, any disease or condition that occurs so infrequently in the United States that there is no reasonable expectation that a medical food for such disease or condition will be developed without assistance under subsection (a). Determinations under the preceding sentence with respect to any drug shall be made on the basis of the facts and circumstances as of the date the request for designation of the drug under section 360bb of this title is made.

  * (3) The term "medical food" means a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.

#### (c) Authorization of appropriations
* For grants and contracts under subsection (a), there is authorized to be appropriated $30,000,000 for each of fiscal years 2018 through 2022.

### §360ff. Priority review to encourage treatments for rare pediatric diseases
#### (a) Definitions
* In this section:

* #### (1) Priority review
  * The term "priority review", with respect to a human drug application as defined in section 379g(1) of this title, means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures of the Food and Drug Administration and goals identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012.

* #### (2) Priority review voucher
  * The term "priority review voucher" means a voucher issued by the Secretary to the sponsor of a rare pediatric disease product application that entitles the holder of such voucher to priority review of a single human drug application submitted under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] after the date of approval of the rare pediatric disease product application.

* #### (3) Rare pediatric disease
  * The term "rare pediatric disease" means a disease that meets each of the following criteria:

    * (A) The disease is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.

    * (B) The disease is a rare disease or condition, within the meaning of section 360bb of this title.

* #### (4) Rare pediatric disease product application
  * The term "rare pediatric disease product application" means a human drug application, as defined in section 379g(1) of this title, that—

    * (A) is for a drug or biological product—

      * (i) that is for the prevention or treatment of a rare pediatric disease; and

      * (ii) that contains no active ingredient (including any ester or salt of the active ingredient) that has been previously approved in any other application under section 355(b)(1), 355(b)(2), or 355(j) of this title or section 351(a) or 351(k) of the Public Health Service Act [42 U.S.C. 262(a), 262(k)];


    * (B) is submitted under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)];

    * (C) the Secretary deems eligible for priority review;

    * (D) that relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population;

    * (E) that does not seek approval for an adult indication in the original rare pediatric disease product application; and

    * (F) is approved after September 30, 2016.

#### (b) Priority review voucher
* #### (1) In general
  * The Secretary shall award a priority review voucher to the sponsor of a rare pediatric disease product application upon approval by the Secretary of such rare pediatric disease product application.

* #### (2) Transferability
  * #### (A) In general
    * The sponsor of a rare pediatric disease product application that receives a priority review voucher under this section may transfer (including by sale) the entitlement to such voucher. There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.

  * #### (B) Notification of transfer
    * Each person to whom a voucher is transferred shall notify the Secretary of such change in ownership of the voucher not later than 30 days after such transfer.

* #### (3) Limitation
  * A sponsor of a rare pediatric disease product application may not receive a priority review voucher under this section if the rare pediatric disease product application was submitted to the Secretary prior to the date that is 90 days after July 9, 2012.

* #### (4) Notification
  * #### (A) Sponsor of a rare pediatric disease product
    * #### (i) In general
      * Beginning on the date that is 90 days after September 30, 2016, the sponsor of a rare pediatric disease product application that intends to request a priority review voucher under this section shall notify the Secretary of such intent upon submission of the rare pediatric disease product application that is the basis of the request for a priority review voucher.

    * #### (ii) Applications submitted but not yet approved
      * The sponsor of a rare pediatric disease product application that was submitted and that has not been approved as of September 30, 2016, shall be considered eligible for a priority review voucher, if—

        * (I) such sponsor has submitted such rare pediatric disease product application—

          * (aa) on or after the date that is 90 days after July 9, 2012; and

          * (bb) on or before September 30, 2016; and


        * (II) such application otherwise meets the criteria for a priority review voucher under this section.

  * #### (B) Sponsor of a drug application using a priority review voucher
    * #### (i) In general
      * The sponsor of a human drug application shall notify the Secretary not later than 90 days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay the user fee to be assessed in accordance with this section.

    * #### (ii) Transfer after notice
      * The sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under clause (i) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification.

* #### (5) Termination of authority
  * The Secretary may not award any priority review vouchers under paragraph (1) after September 30, 2024, unless the rare pediatric disease product application—

    * (A) is for a drug that, not later than September 30, 2024, is designated under subsection (d) as a drug for a rare pediatric disease; and

    * (B) is, not later than September 30, 2026, approved under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)].

#### (c) Priority review user fee
* #### (1) In general
  * The Secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the Secretary a fee determined under paragraph (2). Such fee shall be in addition to any fee required to be submitted by the sponsor under subchapter VII.

* #### (2) Fee amount
  * The amount of the priority review user fee shall be determined each fiscal year by the Secretary, based on the difference between—

    * (A) the average cost incurred by the Food and Drug Administration in the review of a human drug application subject to priority review in the previous fiscal year; and

    * (B) the average cost incurred by the Food and Drug Administration in the review of a human drug application that is not subject to priority review in the previous fiscal year.

* #### (3) Annual fee setting
  * The Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2012, the amount of the priority review user fee for that fiscal year.

* #### (4) Payment
  * #### (A) In general
    * The priority review user fee required by this subsection shall be due upon the notification by a sponsor of the intent of such sponsor to use the voucher, as specified in subsection (b)(4)(A). All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law.

  * #### (B) Complete application
    * An application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary's procedures for paying such fees.

  * #### (C) No waivers, exemptions, reductions, or refunds
    * The Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section.

* #### (5) Offsetting collections
  * Fees collected pursuant to this subsection for any fiscal year—

    * (A) shall be deposited and credited as offsetting collections to the account providing appropriations to the Food and Drug Administration; and

    * (B) shall not be collected for any fiscal year except to the extent provided in advance in appropriations Acts.

#### (d) Designation process
* #### (1) In general
  * Upon the request of the manufacturer or the sponsor of a new drug, the Secretary may designate—

    * (A) the new drug as a drug for a rare pediatric disease; and

    * (B) the application for the new drug as a rare pediatric disease product application.

* #### (2) Request for designation
  * The request for a designation under paragraph (1) shall be made at the same time a request for designation of orphan disease status under section 360bb of this title or fast-track designation under section 356 of this title is made. Requesting designation under this subsection is not a prerequisite to receiving a priority review voucher under this section.

* #### (3) Determination by Secretary
  * Not later than 60 days after a request is submitted under paragraph (1), the Secretary shall determine whether—

    * (A) the disease or condition that is the subject of such request is a rare pediatric disease; and

    * (B) the application for the new drug is a rare pediatric disease product application.

#### (e) Marketing of rare pediatric disease products
* #### (1) Revocation
  * The Secretary may revoke any priority review voucher awarded under subsection (b) if the rare pediatric disease product for which such voucher was awarded is not marketed in the United States within the 365-day period beginning on the date of the approval of such drug under section 355 of this title or section 351 of the Public Health Service Act [42 U.S.C. 262].

* #### (2) Postapproval production report
  * The sponsor of an approved rare pediatric disease product shall submit a report to the Secretary not later than 5 years after the approval of the applicable rare pediatric disease product application. Such report shall provide the following information, with respect to each of the first 4 years after approval of such product:

    * (A) The estimated population in the United States suffering from the rare pediatric disease.

    * (B) The estimated demand in the United States for such rare pediatric disease product.

    * (C) The actual amount of such rare pediatric disease product distributed in the United States.

#### (f) Notice and report
* #### (1) Notice of issuance of voucher and approval of products under voucher
  * The Secretary shall publish a notice in the Federal Register and on the Internet Web site of the Food and Drug Administration not later than 30 days after the occurrence of each of the following:

    * (A) The Secretary issues a priority review voucher under this section.

    * (B) The Secretary approves a drug pursuant to an application submitted under section 355(b) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] for which the sponsor of the application used a priority review voucher under this section.

* #### (2) Notification
  * If, after the last day of the 1-year period that begins on the date that the Secretary awards the third rare pediatric disease priority voucher under this section, a sponsor of an application submitted under section 355(b) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] for a drug uses a priority review voucher under this section for such application, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a document—

    * (A) notifying such Committees of the use of such voucher; and

    * (B) identifying the drug for which such priority review voucher is used.

#### (g) Eligibility for other programs
* Nothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program, including under this chapter, except that no sponsor of a rare pediatric disease product application may receive more than one priority review voucher issued under any section of this chapter with respect to the drug for which the application is made..

#### (h) Relation to other provisions
* The provisions of this section shall supplement, not supplant, any other provisions of this chapter or the Public Health Service Act [42 U.S.C. 201 et seq.] that encourage the development of drugs for tropical diseases and rare pediatric diseases.

#### (i) GAO study and report
* #### (1) Study
  * #### (A) In general
    * Beginning on the date that the Secretary awards the third rare pediatric disease priority voucher under this section, the Comptroller General of the United States shall conduct a study of the effectiveness of awarding rare pediatric disease priority vouchers under this section in the development of human drug products that treat or prevent such diseases.

  * #### (B) Contents of study
    * In conducting the study under subparagraph (A), the Comptroller General shall examine the following:

      * (i) The indications for which each rare disease product for which a priority review voucher was awarded was approved under section 355 of this title or section 351 of the Public Health Service Act [42 U.S.C. 262].

      * (ii) Whether, and to what extent, an unmet need related to the treatment or prevention of a rare pediatric disease was met through the approval of such a rare disease product.

      * (iii) The value of the priority review voucher if transferred.

      * (iv) Identification of each drug for which a priority review voucher was used.

      * (v) The length of the period of time between the date on which a priority review voucher was awarded and the date on which it was used.

* #### (2) Report
  * Not later than 1 year after the date under paragraph (1)(A), the Comptroller General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, a report containing the results of the study under paragraph (1).

### §360ff–1. Targeted drugs for rare diseases
#### (a) Purpose
* The purpose of this section, through the approach provided for in subsection (b), is to—

  * (1) facilitate the development, review, and approval of genetically targeted drugs and variant protein targeted drugs to address an unmet medical need in one or more patient subgroups, including subgroups of patients with different mutations of a gene, with respect to rare diseases or conditions that are serious or life-threatening; and

  * (2) maximize the use of scientific tools or methods, including surrogate endpoints and other biomarkers, for such purposes.

#### (b) Leveraging of data from previously approved drug application or applications
* The Secretary may, consistent with applicable standards for approval under this chapter or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)], allow the sponsor of an application under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act for a genetically targeted drug or a variant protein targeted drug to rely upon data and information—

  * (1) previously developed by the same sponsor (or another sponsor that has provided the sponsor with a contractual right of reference to such data and information); and

  * (2) submitted by a sponsor described in paragraph (1) in support of one or more previously approved applications that were submitted under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act,


* for a drug that incorporates or utilizes the same or similar genetically targeted technology as the drug or drugs that are the subject of an application or applications described in paragraph (2) or for a variant protein targeted drug that is the same or incorporates or utilizes the same variant protein targeted drug, as the drug or drugs that are the subject of an application or applications described in paragraph (2).

#### (c) Definitions
* For purposes of this section—

  * (1) the term "genetically targeted drug" means a drug that—

    * (A) is the subject of an application under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] for the treatment of a rare disease or condition (as such term is defined in section 360bb of this title) that is serious or life-threatening;

    * (B) may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product; and

    * (C) incorporates or utilizes a genetically targeted technology;


  * (2) the term "genetically targeted technology" means a technology comprising non-replicating nucleic acid or analogous compounds with a common or similar chemistry that is intended to treat one or more patient subgroups, including subgroups of patients with different mutations of a gene, with the same disease or condition, including a disease or condition due to other variants in the same gene; and

  * (3) the term "variant protein targeted drug" means a drug that—

    * (A) is the subject of an application under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] for the treatment of a rare disease or condition (as such term is defined in section 360bb of this title) that is serious or life-threatening;

    * (B) modulates the function of a product of a mutated gene where such mutation is responsible in whole or in part for a given disease or condition; and

    * (C) is intended to treat one or more patient subgroups, including subgroups of patients with different mutations of a gene, with the same disease or condition.

#### (d) Rule of construction
* Nothing in this section shall be construed to—

  * (1) alter the authority of the Secretary to approve drugs pursuant to this chapter or section 351 of the Public Health Service Act [42 U.S.C. 262] (as authorized prior to December 13, 2016), including the standards of evidence, and applicable conditions, for approval under such applicable chapter or Act; or

  * (2) confer any new rights, beyond those authorized under this chapter or the Public Health Service Act [42 U.S.C. 201 et seq.] prior to December 13, 2016, with respect to the permissibility of a sponsor referencing information contained in another application submitted under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)].